Clinical trials of small molecule inhibitors in high-grade glioma

Neurosurgery Clinics of North America

Volumn 23, Issue 3, 2012, Pages 407-416

  Day, Samuel E ^a   Waziri, Allen ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical trial; Glioblastoma; Small molecule inhibitor

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANTINEOPLASTIC AGENT; BORTEZOMIB; CARMUSTINE; DASATINIB; DNA TOPOISOMERASE INHIBITOR; ENZASTAURIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; HYDROXYUREA; IMATINIB; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MONOCLONAL ANTIBODY; PAZOPANIB; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE C BETA INHIBITOR; SMALL MOLECULE INHIBITOR; SORAFENIB; SUNITINIB; TANDUTINIB; TEMOZOLOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VORINOSTAT;

CANCER CHEMOTHERAPY; CARCINOGENESIS; DRUG SELECTIVITY; DRUG TARGETING; GENE MUTATION; GLIOBLASTOMA; HUMAN; MOLECULAR SIZE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; GLIOBLASTOMA; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84863007784     PISSN: 10423680     EISSN: 15581349     Source Type: Journal    
DOI: 10.1016/j.nec.2012.04.004     Document Type: Review

References (80)

1. Papac R.J. Origins of cancer therapy. Yale J Biol Med 2001, 74(6):391-398.
2. Westphal M., Hilt D.C., Bortey E., et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 2003, 5(2):79-88.
3. Brem H., Piantadosi S., Burger P.C., et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 1995, 345(8956):1008-1012.
4. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352(10):987-996.
5. Parsons D.W., Jones S., Zhang X., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321(5897):1807-1812.
6. Geyer C.E., Forster J., Lindquist D., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006, 355(26):2733-2743.
7. Motzer R.J., Michaelson M.D., Rosenberg J., et al. Sunitinib efficacy against advanced renal cell carcinoma. J Urol 2007, 178(5):1883-1887.
8. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359(4):378-390.
9. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009, 27(20):3312-3318.
10. Kantarjian H., Sawyers C., Hochhaus A., et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002, 346(9):645-652.
11. Wong A.J., Bigner S.H., Bigner D.D., et al. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci U S A 1987, 84(19):6899-6903.
12. Frederick L., Wang X.Y., Eley G., et al. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 2000, 60(5):1383-1387.
13. The Cancer Genome Atlas Research Network Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455(7216):1061-1068.
14. Rich J.N., Reardon D.A., Peery T., et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004, 22(1):133-142.
15. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350(21):2129-2139.
16. Rich J.N., Rasheed B.K., Yan H. EGFR mutations and sensitivity to gefitinib. N Engl J Med 2004, 351(12):1260-1261. [author reply: 1260-1].
17. Cloughesy T, Yung A, Vrendenberg J, et al. Phase II study of erlotinib in recurrent GBM: Molecular predictors of outcome. J Clin Oncol. 2005 ASCO Annual Meeting Proceedings. 2005.
18. Vogelbaum MA, DP, Stevens G, Barnett G, et al. Phase II trial of the EGFR tyrosine kinase inhibitor erlotinib for single agent therapy of recurrent glioblastoma multiforme: interim results. J Clin Oncol. 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). vol. 22, No 14S (July 15 Supplement), 2004:1558.
19. Franceschi E., Cavallo G., Lonardi S., et al. Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br J Cancer 2007, 96(7):1047-1051.
20. Iwata K.K., Provoncha K., Gibson N. Inhibition of mutant EGFRvIII transformed cells by tyrosine kinase inhibitor OSI-774 (Tarceva). Proc Am Soc Clin Oncol 2002, 21. [abstract: 79].
21. Moscatello D.K., Holgado-Madruga M., Godwin A.K., et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 1995, 55(23):5536-5539.
22. Wikstrand C.J., Hale L.P., Batra S.K., et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 1995, 55(14):3140-3148.
23. van den Bent M.J., Brandes A.A., Rampling R., et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC Brain Tumor Group study 26034. J Clin Oncol 2009, 27(8):1268-1274.
24. Van den Bent M.J., Brandes A.A., Rampling R., et al. Randomized phase II trial of erlotinib versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM): EORTC 26034. Neuro Oncol 2007, 9. [abstract: MA-27].
25. Brown P.D., Krishnan S., Sarkaria J.N., et al. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol 2008, 26(34):5603-5609.
26. Prados M.D., Chang S.M., Butowski N., et al. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol 2009, 27(4):579-584.
27. Jendrossek V., Belka C., Bamberg M. Novel chemotherapeutic agents for the treatment of glioblastoma multiforme. Expert Opin Investig Drugs 2003, 12(12):1899-1924.
28. Raymond E., Brandes AA., Dittrich C., et al. Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J Clin Oncol 2008, 26(28):4659-4665.
29. Wen P.Y., Yung W.K., Lamborn K.R., et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res 2006, 12(16):4899-4907.
30. Viola F.S., Katz A., Arantes A., et al. Barrios phase II trial of high dose imatinib in recurrent glioblastoma multiforme (GBM) with platelet derived growth factor receptor (PDGFR) expression. J Clin Oncol 2007, 25(Suppl 18). ASCO Annual Meeting Proceedings Part I J Clin Oncol (Meeting Abstracts) 2007;25(18 Suppl):2056.
31. Razis E., Selviaridis P., Labropoulos S., et al. Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment. Clin Cancer Res 2009, 15(19):6258-6266.
32. Raymond E., Brandes Alba A., Dittrich Ch, et al. Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group study. J Clin Oncol 2008, 26:4659-4665.
33. Dresemann G. Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. Ann Oncol 2005, 16(10):1702-1708.
34. Reardon D.A., Egorin M.J., Quinn J.A., et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol 2005, 23(36):9359-9368.
35. Dresemann G., Weller M., Rosenthal M.A., et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. J Neurooncol 2010, 96(3):393-402.
36. Oehring R.D., Miletic M., Valter M.M., et al. Vascular endothelial growth factor (VEGF) in astrocytic gliomas-a prognostic factor?. J Neurooncol 1999, 45(2):117-125.
37. Conrad C., Friedman H., Reardon D., et al. A phase I/II trial of single-agent PTK 787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM). Proc Am Soc Clin Oncol 2004, 22.
38. Reardon D., Friedman H., Yung W.K.A., et al. A phase I/II trial of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM). Proc Am Soc Clin Oncol 2004, 22.
39. Sathornsumetee S., Desjardins A., Vredenburgh J.J., et al. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol 2010, 12(12):1300-1310.
40. Sathornsumetee S., Desjardins A., Vredenburgh J.J., et al. Phase II trial of bevacizumab plus erlotinib for patients with recurrent malignant gliomas: final results. J Clin Oncol 2010, 28(Suppl 15). [Suppl; abstract: 2055].
41. Batchelor T.T., Sorensen A.G., di Tomaso E., et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11(1):83-95.
42. Maehama T., Dixon J.E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998, 273(22):13375-13378.
43. Mellinghoff I.K., Wang M.Y., Vivanco I., et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005, 353(19):2012-2024.
44. Smith J.S., Tachibana I., Passe S.M., et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 2001, 93(16):1246-1256.
45. Wilhelm S.M., Carter C., Tang L., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64(19):7099-7109.
46. Hainsworth J.D., Ervin T., Friedman E., et al. Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme. Cancer 2010, 116(15):3663-3669.
47. Reardon D.A., Vredenburgh J.J., Desjardins A., et al. Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. J Neurooncol 2011, 101(1):57-66.
48. Kleber S., Sancho-Martinez I., Wiestler B., et al. Yes and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell 2008, 13(3):235-248.
49. Chakravarti A., Zhai G., Suzuki Y., et al. The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol 2004, 22(10):1926-1933.
50. Momota H., Nerio E., Holland E.C. Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. Cancer Res 2005, 65(16):7429-7435.
51. Cloughesy T.F., Yoshimoto K., Nghiemphu P., et al. Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 2008, 5(1):e8.
52. Galanis E., Buckner J.C., Maurer M.J., et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 2005, 23(23):5294-5304.
53. Chang S.M., Wen P., Cloughesy T., et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 2005, 23(4):357-361.
54. Carducci M.A., Musib L., Kies M.S., et al. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol 2006, 24(25):4092-4099.
55. Fine H.A., Kim L., Royce C. Results from phase II trial of enzastaurin (LY317615) in patients with recurrent high grade gliomas. J Clin Oncol 2005, 23(Suppl 115). [abstract: 1504].
56. Fine H.A., Kim L., Royce C., et al. A phase II trial of LY317615 in patients with recurrent high grade gliomas. J Clin Oncol 2004, 22. [abstract: 1511].
57. Fine H.A., PV, Chamberlain M.C., et al. Enzastaurin (ENZ) versus lomustine (CCNU) in the treatment of recurrent, intracranial glioblastoma multiforme (GBM): a phase III study. J Clin Oncol 2005, 26. [abstract: 2005].
58. Puduvalli V.K., Wick W., Chamberlain M.C., et al. Enzastaurin versus lomustine in the treatment of recurrent, intracranial glioblastoma: a phase III study. Neuro Oncol 2008, 10. [abstract: MA-35].
59. Thornton D., Graff J. Enzastaurin: an introduction to a new, targeted agent for the treatment of glioblastoma multiforme. Neuro Oncol 2006, 8. [abstract: P142].
60. Wick W., Puduvalli V.K., Chamberlain M.C., et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 2010, 28(7):1168-1174.
61. Friedman H.S., Petros W.P., Friedman A.H., et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 1999, 17(5):1516-1525.
62. Chamberlain M.C. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. J Neurooncol 2002, 56(2):183-188.
63. Prados M.D., Lamborn K., Yung W.K., et al. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol 2006, 8(2):189-193.
64. Buckner J.C., Reid J.M., Wright K., et al. Irinotecan in the treatment of glioma patients: current and future studies of the North Central Cancer Treatment Group. Cancer 2003, 97(Suppl 9):2352-2358.
65. Batchelor T.T., Gilbert M.R., Supko J.G., et al. Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11. Neuro Oncol 2004, 6(1):21-27.
66. Vredenburgh J.J., Desjardins A., Herndon J.E., et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007, 13(4):1253-1259.
67. Vredenburgh J.J., Desjardins A., Herndon J.E., et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007, 25(30):4722-4729.
68. Reardon D.A., Desjardins A., Vredenburgh J.J. Bevacizumab plus etoposide among recurrent malignant glioma patients: phase II study final results. J Clin Oncol 2009, 27(Suppl 15). [abstract: 2046].
69. Conley B.A., Wright J.J., Kummar S. Targeting epigenetic abnormalities with histone deacetylase inhibitors. Cancer 2006, 107(4):832-840.
70. Chinnaiyan P., Vallabhaneni G., Armstrong E., et al. Modulation of radiation response by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys 2005, 62(1):223-229.
71. Sawa H., Murakami H., Kumagai M., et al. Histone deacetylase inhibitor, FK228, induces apoptosis and suppresses cell proliferation of human glioblastoma cells in vitro and in vivo. Acta Neuropathol 2004, 107(6):523-531.
72. MacDonald T.J., Taga T., Shimada H., et al. Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist. Neurosurgery 2001, 48(1):151-157.
73. Nabors L.B., Mikkelsen T., Rosenfeld S.S., et al. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol 2007, 25(13):1651-1657.
74. Stupp R., Hegi M.E., Neyns B., et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 2010, 28(16):2712-2718.
75. Chamberlain M.C. What role should cilengitide have in the treatment of glioblastoma?. J Clin Oncol 2010, 28(33):e695.
76. Mani A., Gelmann E.P. The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol 2005, 23(21):4776-4789.
77. Friday B.B., Anderson S.K., Buckner J., et al. Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma multiforme: a north central cancer treatment group study. Neuro Oncol 2010, 12(4):iv69-iv78.
78. Stommel J.M., Kimmelman A.C., Ying H., et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007, 318(5848):287-290.
79. Huang T.T., Sarkaria S.M., Cloughesy T.F., et al. Targeted therapy for malignant glioma patients: lessons learned and the road ahead. Neurotherapeutics 2009, 6(3):500-512.
80. Verhaak R.G., Hoadley K.A., Purdom E., et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17(1):98-110.